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Abstract
OBJECTIVES: The study aimed to evaluate the feasibility of off-pump transapical mitral valve-in-ring implantation and to test the per-
formance of a custom-made self-expandable stent valve, in comparison with the standard SAPIEN valve.
METHODS: Acute experiments were performed in ﬁve pigs. Animals (mean weight 58.4 ± 7.3 kg) underwent mitral valve annuloplasties
under cardiopulmonary bypass using 26-mm rings (SJM™). Then, a 30-mm custom-made self-expandable stent valve or a 23-mm
balloon-expandable transcatheter heart valve (Edwards SAPIEN XT™) was deployed within the annuloplasty rings through a transatrial
access and under direct vision. Subsequently, the stent valves were inserted transapically under ﬂuoroscopic guidance and off pump.
RESULTS: The procedural success of transatrial and transapical mitral valve-in-ring procedures was 100% (10 of 10). Mean transatrial
and transapical procedure time was 2.0 ± 1.1 and 22.0 ± 5.7 min, respectively. Haemodynamic status during transapical implantation
remained stable, and differences in data collected before and after the stent-valve deployment were not statistically signiﬁcant. Mean
mitral annulus diameter and mean mitral oriﬁce area in the group of self-expandable stent valves were 2.60 ± 0.02 cm and 4.16 ± 0.48
cm2, respectively, whereas in the SAPIEN group they were 1.95 ± 0.18 cm and 2.26 ± 0.20 cm2, respectively. Trace or mild regurgitation
was detected only in the self-expandable stent-valve group. Mean gradients were 4.1 ± 4.5 mmHg across the self-expandable stent
valves and 1.0 ± 0 mmHg across the SAPIEN valves. Postmortem examination conﬁrmed adequate positioning of the self-expandable
valves and the SAPIEN valves within the annuloplasty ring.
CONCLUSIONS: Off-pump transapical mitral valve-in-ring implantation is safe and feasible. Transapical access may represent the ideal
option for valve-in-ring procedures in cases of recurrent mitral regurgitation after mitral valve repair, in high-risk patients. Owing to the
supra-annular proﬁle of the valve components, our custom-made nitinol stent valve provides nearer to normal functional area than the
SAPIEN valve.
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INTRODUCTION
Mitral valve repair using an annuloplasty ring is the optimal
surgical therapy for mitral regurgitation (MR). Some clinical
studies have revealed the superiority of mitral valve repair over
replacement [1, 2], including elderly patients [3]. Although ac-
ceptable early mitral valve repair results were demonstrated,
recent studies have called into question the durability of mitral
valve repair in some patients. They have documented the de-
velopment of recurrent MR after repair for degenerative aeti-
ologies to be 2–4% per year [4, 5]. Some centres reported that
recurrence of severe mitral valve regurgitation following valve
repair is up to 30% at 6 months [4, 6, 7], and some of them
require redo cardiac surgery. However, not only the surgeons
but also the patients have to take into consideration the chal-
lenge of redo surgery, especially in the case of elderly high-risk
patients.
Recently, transcatheter valve replacement techniques have
been developed to offer patients less invasive alternatives to
open heart surgery. Transfemoral and transapical implantation of
aortic and pulmonary stent valves have shown promising clinical
results. Moreover, transcatheter mitral valve replacement is also
under evaluation and, based on this development, some recently
published clinical reports and animal studies have conﬁrmed the
feasibility of transcatheter mitral valve-in-valve or valve-in-ring
implantation [8–11]. Thus, the valve-in-ring technique turns out
to be a potential therapeutic technique for high-risk patients
with mitral repair failure.
This study was designed to conﬁrm the feasibility of transapical
transcatheter mitral valve-in-ring replacement without cardiopul-
monary bypass (CPB) support using a custom-made self-
expandable nitinol stent valve, and to evaluate the haemodynamic
performances compared with the conventional SAPIEN heart
valve (Edwards Lifesciences, Irvine, CA, USA), in a porcine model.
© The Author 2012. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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MATERIALS AND METHODS
The stent valve
Two different stent valves were employed, as follows.
(i) A 30-mm self-expandable stent with a double-crown design
was manufactured as described in a previous article [12]. It is
composed of two self-expandable nitinol Z-stents covered
by an ultra-thin polytetraﬂuoroethylene membrane, that
were sutured together like two opposite crowns, for the
annular ﬁxation. A 30-mm diameter Dacron tube is attached
at the centre of the ﬁxation system and it accommodates a
unidirectional trileaﬂet semilunar valve created in-house with
commercial porcine pericardium (Vascutek, Swillington, UK;
Fig. 1A). All stent valves were tested in vitro prior to the ex-
periment in vivo and then stored in glutaraldehyde solution.
(ii) A 23-mm Edwards SAPIEN XT™ balloon-expandable trans-
catheter heart valve (Edwards Lifescience, Irvine, CA, USA;
Fig. 1B).
The delivery system
(i) A self-constructed Teﬂon sheath delivery system was
employed in vivo. It consisted of a 30-cm-long sheath and a
pusher with a blunt tip. The sheath, including the
stent-loading capsule, was made based on a modiﬁed 18
French commercial introducer sheath (B. Braun Melsungen
Ag, Melsungen, Gemany). The distal end of the sheath was
dilated up to a 30 French inner lumen diameter by inﬂating
a 10-mm balloon (Boston Scientiﬁc Corp., Watertown, MA,
USA). On the basis of the length of the stent, a 40-mm
capsule was created [13]. Then, the stent valve was com-
pressed with a commercial crimper and loaded into the
capsule. The valve deployment in the appropriate position
was performed with a pusher into the sheath and without
balloon catheters (nitinol stent). The folded valve measured
10 mm in diameter and 40–43 mm in length (Fig. 2A).
(ii) Ascendra2 transapical delivery system (Edwards Lifescience,
Irvine, CA, USA; Fig. 2B).
Animal preparation
Animals received care in compliance with the Principles
of Laboratory Animals formulated by the National Society of
Medical Research and the Guide for the Care and Use of
Laboratory Animals prepared by the Institute of Laboratory
Animal Resources and published by the US National Institutes of
Health (NIH publication no. 85-23, revised 1985). The protocol
was approved by the Institutional Committee on Animal
Research.
Five pigs (mean weight 58.4 ± 7.3 kg, 9–12 weeks, female)
were included in our study for acute evaluation. After induction
Figure 1: Two different stent valves were used: a self-expandable stent valve
(A) and the Edwards SAPIEN balloon-expandable transcatheter heart valve (B).
Figure 2: The custom-made delivery system, which loads the self-expandable
stent valve (A), and the Ascendra2 transapical delivery system, which loads
the Edwards SAPIEN valve (B).
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of general anaesthesia, with tracheal intubation and mechanical
ventilation (ketamine 22 mg/kg and atropine 0.8 mg/kg intra-
muscularly; thiopental 15 mg/kg intravenously for induction; and
isoﬂurane 2.5% for maintenance of anaesthesia), the right carotid
artery and internal jugular vein were exposed, and catheters
were introduced to monitor the blood pressure (BP) and the
central venous pressure (CVP), and for blood sampling and infu-
sion. The left carotid artery and the external jugular vein were
prepared for cannulation for CPB. The right femoral vein was
also exposed for insertion of an intracardiac ultrasonic probe
(ICUS; Accuson Navigate, Acuson, Siemens, Munich, Germany).
Continuous monitoring of electrocardiography, arterial pressure,
central venous pressure and oxygen saturation was routine.
Annuloplasty ring implantation and transatrial
stent-valve implantation
After standard sternotomy and heparinization (Liquemine; La
Roche Ltd, Basel, Switzerland; 100 IU/kg), the native mitral
annular diameter was measured by ICUS. CPB was instituted
with cannulation of the left carotid artery and external jugular
vein. After aortic cross-clamping, antegrade cardioplegia was
administered and the heart arrested. After opening of the left
atrium from the left side, a 26-mm SJM™ Séguin semi-rigid
annuloplasty ring (St Jude Medical Inc., St Paul, MN, USA)
custom-marked by titanium clips was sutured at the standard
position of the mitral annulus (Fig. 3). Saline injection tests were
performed to evaluate the mitral valve closure. Transatrial stent-
valve implantation was performed under direct vision. The ven-
tricular side of the self-expandable stent valve was released by
sliding the pusher once the delivery system was placed across
the ring; then, we gently pulled the introducer back in order to
deploy the atrial side. Regarding the balloon-expandable valve,
the delivery system was introduced within the ring and then
inﬂated at the proper position. The heart was de-aired, and the
aortic cross-clamp was removed after atrial closure. Once off
pump, the ICUS was performed. The trans-stent and left ven-
tricular outﬂow tract (LVOT) pressure gradient were measured
with a needle. After all measurements were completed, a second
cardiac arrest was induced on pump with cardioplegic solution,
and the stent valve was removed. The left atrium was closed, the
aortic cross-clamp removed and the CPB stopped with stable
haemodynamics.
Transapical mitral stent-valve implantation
Self-expandable stent-valve implantation (n = 4). A double
2–0 purse-string monoﬁlament pledgeted felt suture was placed
at the left ventricular apex. The apex was punctured with a
needle followed by a guide wire and an 8 French introducer
system (Arrows, Reing, PA, USA) inserted into the left ventricle.
Several titanium clips placed on the ring were seen as a dotted
circle under ﬂuoroscopy. A soft-tipped, stiff guidewire (0.89 mm,
180 cm; Boston Scientiﬁc, Natick, MA, USA) was introduced into
the left ventricle, through the ring, and positioned in a left
pulmonary vein. A pigtail catheter was advanced for exchanging
the stiff wire. Then, a super-stiff guidewire (TSMG-35-26O-LES;
Cook Medical, Limerick, Ireland) was exchanged using the pigtail
catheter. A 30 French Ascendra2 Introducer Sheath Set (Edwards
Lifescience) was used to dilate the transapical access and then
removed, and the bleeding was controlled by tightening the
purse-string sutures. The custom-made delivery system loaded
with the self-expandable stent valve was pushed along the rigid
guidewire, until the middle of the stent valve reached the mitral
ring. Without rapid ventricular pacing, the atrial side of the stent
partly expanded by advancing the pusher. We withdrew the
delivery system gradually until the ﬁxation portion of the stent
was at the level of the ring, and then we gently pulled back the
delivery sheath to deploy the ventricular side (Fig. 4A–D).
Edwards SAPIEN valve implantation (n = 1). The transapical
access was established as described above. A 23-mm SAPIEN
valve was mounted on the delivery balloon and introduced
through the ring under ICUS and ﬂuoroscopy guidance. Once in
position, the stent was deployed following the standard
technique (Fig. 4E and F).
After implantation, the ICUS was used to evaluate the function
and competence of the stent valve for at least 30 min. The
trans-stent and LVOT pressure gradients were measured directly
with a needle. Thereafter, haemodynamic parameters were con-
tinuously recorded for at least 1 h. The animals were then killed
by an iv injection of Phenobarbital to permit inspection of the
position of the stent valves in the rings.
Statistical analysis
Data were analysed with SPSS19 software for Windows. Variables
are reported as means ± standard deviation (SD), and Student’s
paired t-test was used for comparison.
RESULTS
Annuloplasty rings were successfully implanted in all animals.
Mean heart arrest time and CPB time were 19.0 ± 3.1 and 53.6 ±
4.9 min, respectively. The procedural success of transatrial and
transapical mitral valve-in-ring was 100%. Custom-made self-
expandable nitinol stent valves (30 mm) and 23-mm Edwards
SAPIEN XT balloon-expandable transcatheter heart valves were
used for comparison. The number of implanted stent valves and
Figure 3: The 26 mm semi-rigid annuloplasty ring was sutured at the mitral
annulus under cardiopulmonary bypass (viewed and implanted from the left
side). Clips were placed to the ring to be visualized under ﬂuoroscopy.
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the implanted access are showed in Table 1. Mean transatrial
and transapical procedure times were 2.0 ± 1.1 and 22.0 ± 5.7
min, respectively. Haemodynamic data before and after transapi-
cal valve deployment are showed in Table 1.
The mean diameter of the native mitral annulus was 2.54 ±
0.13 cm, and the mean mitral valve area was 4.81 ± 0.52 cm2 in
ICUS evaluation. Comparatively, they were 2.60 ± 0.20 cm and
4.16 ± 0.48 cm2 in the group of self-expandable stents and 1.95
± 0.18 cm and 2.26 ± 0.20 cm2 in the group of SAPIEN valves, re-
spectively, after implantation. All valves within the stents opened
and closed completely and functioned well (Fig. 5). In the self-
expandable stents, trace or mild central regurgitation was
detected. A mild leak between the stent and the ring also
existed in one of them. No regurgitation was observed in the
SAPIEN valves (Table 2). The mean pressure gradient across the
self-expandable stent was 4.1 ± 4.5 mmHg, and across
the SAPIEN valve the gradient was 1.0 ± 0 mmHg. The
corresponding gradients across the LVOT were 3.0 ± 1.0 and 2.5
± 2.1 mmHg, respectively (Table 2).
Postmortem examinations conﬁrmed good positioning of the
stents within the annuloplasty rings in all animals, without LVOT
obstruction (Fig. 6).
DISCUSSION
With the development of transcatheter aortic valve replacement,
transapical access has become a routine approach for the im-
plantation of transcatheter aortic valve prostheses because of its
safety, reproducibility and low complication rate. Allowance for
implantation of large devices and short access to both the mitral
and the aortic valve are considered to be its main advantages
[14]. Despite these superior attributes, the interference of the
mitral valve apparatus with the delivery system still has a
Figure 4: The custom-made self-expandable stent valve was delivered (A–C) and anchored to the annuloplasty ring (white arrows; D). The Edwards SAPIEN valve
was accurately positioned within the annuloplasty ring, marked with a titanium clip (white arrows; E and F). The stent retained the ‘round’ shape (F).
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negative inﬂuence in spreading this access to transcatheter mitral
valve replacements [15]. Several teams did some work on it and
reported their clinical and animal studies, including replacement
of native mitral valves and mitral valve-in-valve procedures for
degenerated bioprostheses [8, 16, 17]. Nevertheless, up to now
no experimental studies have been published on a transapical
mitral valve-in-ring procedure.
In our study, we successfully performed transapical mitral
valve-in-ring implantations using two different types of stent
valves, and there were no signiﬁcant differences in terms of
haemodynamics, heart rate, blood pressure and CVP before and
after the valve implantation (P > 0.05). This ﬁnding attests to the
feasibility of transapical mitral valve-in-ring implantations
without CPB.
So far, the available balloon-expandable Edwards SAPIEN
transcatheter heart valve has been the only valve used in reports
on mitral valve-in-valve or valve-in-ring procedures, and this
reﬂects its promising results and its excellent low proﬁle and
performing delivery system. The main problem of the
valve-in-ring technique is matching the size between the stent
valve and the mitral ring. Joerg Kempfert and colleagues
reported in their tests that the 23- and 26-mm SAPIEN valves
ﬁtted well within annuloplasty ring sizes up to 26 and 28 mm,
respectively. An oversized ring may result in median or severe
central MR because the stent may expand excessively and may
become dislodged [9]. In our study, the 23-mm SAPIEN valve
matched the 26-mm ring very well. No central or perivalvular
regurgitation was recorded, and dislodgement of the stent valve
never happened. On the contrary, a conformational change of
shape in SAPIEN valves from ‘round’ to ‘oval’ when implanted
into the ring was described in previous studies, but this was not
observed in our series [9, 10]. In fact, when the stent expanded,
its shape remained ‘round’, whereas the ‘D’-shaped annuloplasty
ring became circular (Fig. 4F). Postmortem examination also con-
ﬁrmed this ﬁnding (Fig. 6C), and this contradiction is probably
due to the use of semi-rigid annuloplasty rings in our study. A
beneﬁt resulting from this change of shape is the maintainance
of normal valve haemodynamics and a reduction in the risk of
perivalvular and/or intravalvular regurgitation.
We also found that the stent-valve oriﬁce area (2.26 ± 0.20
cm2) after the implantation of a SAPIEN valve into the ring was
signiﬁcantly lower compared with the surface area of the native
mitral valve (4.80 ± 0.60 cm2; P < 0.05). This result is a relative
valve undersizing and could appear to be suboptimal in clinical
cases.
There are some advantages in a self-expanding valve design,
such as the potential for the positioning of stent-valve compo-
nents in a supra-annular fashion, allowing for a larger oriﬁce
area. In our study, the resulting oriﬁce area was indeed superior
to the ones measured through the SAPIEN valves, but the trans-
valvular gradient pressures were suboptimal because of the
Figure 5: An intracardiac ultrasonic probe (ICUS) was employed to evaluate
the performances of the implanted self-expandable stent valve (A) and the
Edwards SAPIEN valve (B). Both valve types were functioning well.
Table 1: Procedural and haemodynamic data
Animal no. Weight (kg) Stent HRa
(beats/min)
BPa
(mmHg)
CVPa
(mmHg)
ECG Arrest time
(min)
CPB time
(min)
Tap time
(min)
Tat Tap B A B A B A B A
1 50 C C 50 47 56/23 47/12 6 5 NS NS 20 57 30
2 55 C C 92 102 76/31 76/38 5 8 NS NS 23 53 25
3 65 S C 102 120 73/44 92/35 10 7 NS NS 15 48 20
4 55 C S 103 56 81/45 91/23 6 12 NS NS 17 50 20
5 67 S C 132 50 82/29 71/26 5 5 NS NS 20 60 15
aDifferences between haemodynamics before and after the valve-in-ring implantation were not statistically significant. A: after transapical implantation; B:
before transapical implantation; BP: blood pressure; CPB: cardiopulmonary bypass; C: custom-made stent valve; CVP: central venous pressure; ECG:
electrocardiography; HR: heart rate; NS: normal sinus; S: SAPIEN valve; Tap: transapical; Tat: transatrial.
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amount of material within the stent. As described in the previous
paragraph, a Dacron tube for accommodating a valve was an
extra component in our stent compared with the SAPIEN valve.
Moreover, this tube was soft and might be partly deformed
while the blood ﬂow went through. All of these factors resulted
in higher transvalvular gradient pressures. We will further opti-
mize the design of the stent in future experiments.
Based on our previous experience [12], the double-crown self-
expandable valve was modiﬁed using porcine pericardium to
replace the previous aortic and pulmonary valve homografts,
and several advantages appeared when this prototype was
compared with the SAPIEN valve, as follows: (i) a larger (diam-
eter > 28 mm) stent could be applied; (ii) the structure of the
double crown ﬁts extremely well into the annuloplasty ring, and
the ring offers an appropriate position for the ﬁxation of the
stent valve; (iii) no rapid pacing is required during the
implantation; and (iv) the oriﬁce valve area after the implant-
ation (4.16 ± 0.48 cm2) approximated the native valve area (4.81
± 0.52 cm2; P = 0.297 > 0.05). We think that our custom-made
double-crown stent valve is more suitable for valve-in-ring pro-
cedures than the SAPIEN valve. However, in one case we
detected a mild central and persistent regurgitation with high
transvalvular pressures (15 mmHg); the probable reason for high
gradients in this case was that the regurgitation resulted in an in-
crease in the left ventricular end-diastolic pressure.
In conclusion, the present study demonstrated the feasibility
of transapical mitral valve-in-ring implantations without extracor-
poreal circulation. The transapical technique developed for
the Edwards SAPIEN stent-valve implantation shows promising
performances in valve-in-ring procedures. Moreover, new self-
expandable stent valves implanted through transapical access show
good haemodynamic results with better functional valve areas.
Figure 6: At postmortem examination, the custom-made self-expandable stent (A, left atrial side; B, left ventricular side) and the Edwards SAPIEN valve (C, left
atrial side; D, left ventricular side) were positioned accurately within the annuloplasty ring, without left ventricular outﬂow tract (LVOT) obstruction. The ‘D’-shaped
annuloplasty ring became near to circular in the presence of the fully expanded SAPIEN stent valve (C).
Table 2: Implanted stent-valve function
Self-expandable valves Edwards SAPIEN valves
Stent number n = 7 n = 3
Pressure gradient across the valve (mmHg) 4.1 ± 4.5 1.0 ± 0
Pressure gradient across the left ventricular outflow tract (mmHg) 3.0 ± 1.0 2.5 ± 2.1
Mitral regurgitation Trace or mild No
Native Stent Native Stent
Valve diameter (cm) 2.54 ± 0.13 2.60 ± 0.02 2.53 ± 0.13 1.95 ± 0.18
Valve area (cm2) 4.81 ± 0.52 4.16 ± 0.48 4.80 ± 0.60a 2.26 ± 0.20a
aThere was a significant difference between the area of the implanted Edwards SAPIEN valves and the native mitral valve orifice area.
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LIMITATIONS
The study was an acute test in animals. The long-term durability
and haemodynamics of both stent valves in rings are unknown.
The ﬁxation stability of stents in mitral rings needs to be con-
ﬁrmed by long-term studies.
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